Vizgen Showcases Benefits of Spatial Genomics Platform in Understanding the Tumor Microenvironment at AACR 2022 Annual Meeting
Pioneering the next generation of genomics, Vizgen unveils new workflow to perform in situ single-cell transcriptomic imaging in FFPE tissue sections with MERSCOPE™ Platform
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it will be presenting a poster at the 2022 American Association for Cancer Research (AACR) Annual Meeting. Conducted with Massachusetts General Hospital (MGH), the University of California San Francisco (UCSF), The Broad Institute, and Harvard Medical School (HMS), the poster will report how a spatially resolved map of colorectal cancer can best identify novel spatial relationships between cancer cells and the microenvironment. An e-poster will be made available beginning on Friday, April 8 at 1 p.m. ET.
Poster Presentation Details:
Title: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment
Presenting Author: Colles Price, MS, Ph.D., Senior Research Scientist – Oncology Lead, Vizgen
Abstract #: 2030
Session Title: Spatial Proteomics and Transcriptomics
Session Date and Time: April 11, 2022, 1:30 p.m. – 5:00 p.m.
Location: New Orleans Convention Center, Poster Section 34, Poster Board #8
In addition to the company’s poster presentation at AACR, Vizgen showcased preliminary data performing in situ single-cell transcriptomic imaging in formalin-fixed paraffin-embedded (FFPE) tissue sections with its MERSCOPE™ platform, powered by multiplexed error robust in situ hybridization (MERFISH) technology. FFPE tissues are the most widely used clinical sample types in histology and molecular diagnosis. However, due to RNA degradation and protein crosslinking, FFPE samples are often not compatible with single-cell transcriptomic analysis. Dr. Jiang He, Scientific Co-founder and Senior Director of Scientific Affairs at Vizgen, recently presented a webinar demonstrating MERFISH imaging in more than 15 FFPE sample types from mouse and human, including archival clinical samples. The webinar can be viewed here.
“We are buoyed by the tremendous adoption of MERSCOPE since the platform’s U.S. launch in the beginning of the year as customers realize the vast benefits of a high multiplexing, high resolution in situ platform to combine single-cell and spatial genomics,” said Terry Lo, President and CEO of Vizgen. “Spatial context, as underscored by the presentation at AACR, is critical to advancing therapies for immunologically distinct colon cancer types and the high resolution and sensitivity of MERSCOPE data has the potential to aid researchers in uncovering new findings in the tumor microenvironment.”
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE™ Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.